Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an ...

The role of the ubiquitin ligase UBE4B in neural tumors in adults and children. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...

The first FDA-approved systemic therapy may be beneficial to patients with low-grade astrocytoma or oligodendroglioma with IDH1 or 2 mutations. The recent Food and Drug Administration (FDA) approval ...

Brain tumors cannot always be successfully treated with conventional therapies. A team from Empa and the hospital network HOCH Health Ostschweiz is therefore developing nanozymes that can attack ...

This type of brain tumor can range from slow-growing to highly aggressive forms. Learn how astrocytomas are diagnosed and treated and what factors influence a person’s outlook and recovery.

Single institution analysis of glioblastoma multiforme (GBM) outcomes based on year of diagnosis: A 17 year review. Personalized neoantigen-pulsed autologous dendritic cells vaccine as an adjuvant ...

A team from Empa and HOCH Health Ostschweiz is developing nanomaterials that can be applied directly during surgery to attack ...

Astrocytoma is the most common type of glioma tumour affecting the brain and spinal cord. Originating from star-shaped brain cells called astrocytes, astrocytomas account for nearly 50% of all primary ...